Home-Based Corrective Exercise With Remote Reinforcement for Upper Crossed Syndrome

November 4, 2026 updated by: JORGE MONTERO CÁMARA, Cardenal Herrera University

Effects of a Home-Based Corrective Exercise Program With Active Remote Reinforcement on Craniovertebral Angle, Rounded Shoulder Posture, Thoracic Kyphosis, Pain, Cervical and Shoulder Disability, and Pulmonary Function i Adults With Upper Crossed Syndrome: A Two-Arm Parallel Randomized Controlled Trial

Upper Crossed Syndrome (UCS) is a musculoskeletal condition defined by simultaneous forward head posture (craniovertebral angle, CVA < 52°), rounded shoulders (RSP > 52°), and thoracic hyperkyphosis (> 42°). It is highly prevalent in sedentary workers and musicians and is associated with neck pain, shoulder pain, and reduced pulmonary function. This two-arm parallel randomized controlled trial will compare two home-based corrective exercise programs over 12 weeks in adults with confirmed UCS. Both groups (Experimental, EG; Control, CG) perform the same 20-minute program three times per week: diaphragmatic breathing re-education and targeted muscle strengthening and stretching. The EG additionally uses a volumetric incentive spirometer (Coach2, 4000 mL) as respiratory biofeedback and receives active remote reinforcement (biweekly video calls + asynchronous educational material from a physiotherapist); the CG performs the same exercises without the spirometer and receives only minimal adherence monitoring. Outcomes are assessed at baseline (week 0) and at weeks 4, 8, and 12. Primary outcome: craniovertebral angle (CVA) measured by lateral photogrammetry. Secondary outcomes: rounded shoulder angle (RSP), thoracic kyphosis (bubble inclinometer and smartphone inclinometer), pain (Visual Analogue Scale), cervical disability (Neck Disability Index), shoulder pain and disability (SPADI), exercise adherence, and pulmonary function (spirometry: FVC, FEV₁/FVC, MVV) at weeks 0 and 12. Recruitment will take place at the Associació Amics de la Música de Meliana, Fisioterapia A Punto, and Universidad Cardenal Herrera CEU (Valencia, Spain). A total of 96 participants (48 per arm) will be enrolled over a 2-year recruitment window.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
96

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • • Confirmed UCS diagnosis, defined by the simultaneous presence of: (a) craniovertebral angle (CVA) < 52°; (b) rounded shoulder posture angle (RSP) > 52°; and (c) thoracic kyphosis angle > 42°.

    • Age between 18 and 65 years.
    • Available and willing to perform the home exercise program and to attend all four face-to-face assessment sessions (weeks 0, 4, 8, and 12).
    • Access to a camera-equipped device (smartphone or tablet) for remote monitoring and reinforcement.
    • Ability to understand the study procedures and to sign informed consent.

Exclusion Criteria:

  • Severe cervical or thoracic pathology: vertebral fracture, neoplasm, infection, or active systemic inflammatory disease.

    • Spinal surgery within the preceding 12 months.
    • Respiratory pathology contraindicating use of a volumetric incentive spirometer: recent pneumothorax (< 6 weeks), COPD GOLD grade III-IV, or unstable bronchial asthma.
    • Active physiotherapy treatment specifically targeting UCS within the preceding 3 months.
    • Pregnancy or breastfeeding.
    • Cognitive impairment or language barrier preventing comprehension of the exercise program.
    • Simultaneous participation in another clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental Group (EC)

Home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) combining: (1) diaphragmatic breathing re-education with a volumetric incentive spirometer (Coach2, 4000 mL, Smiths Medical) as biofeedback - 4 progressive levels, 10 repetitions; (2) muscle strengthening and stretching targeting the deep cervical flexors, lower and middle trapezius, rhomboids, and pectoral/suboccipital muscles. The EG additionally receives active remote reinforcement: a biweekly video call with a physiotherapist and asynchronous educational material (written guides and video tutorials) delivered via a messaging platform.
Device: Home-based corrective exercise program with incentive spirometer and remote reinforcement

Home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) combining: (1) diaphragmatic breathing re-education with a volumetric incentive spirometer (Coach2, 4000 mL, Smiths Medical) as biofeedback - 4 progressive levels, 10 repetitions; (2) muscle strengthening and stretching targeting the deep cervical flexors, lower and middle trapezius, rhomboids, and pectoral/suboccipital muscles. The EG additionally receives active remote reinforcement: a biweekly video call with a physiotherapist and asynchronous educational material (written guides and video tutorials) delivered via a messaging platform.
Active Comparator: Control Group (CG)

Identical home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) with the same muscle strengthening and stretching exercises. The CG does not use an incentive spirometer (diaphragmatic breathing performed without device) and does not receive active remote reinforcement; adherence monitoring is minimal (standardized paper diary).
Behavioral: Home-based corrective exercise program (no spirometer, minimal follow-up)

Identical home-based corrective exercise program (3 sessions/week × 12 weeks, 20 min/session) with the same muscle strengthening and stretching exercises. The CG does not use an incentive spirometer (diaphragmatic breathing performed without device) and does not receive active remote reinforcement; adherence monitoring is minimal (standardized paper diary).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Craniovertebral Angle (CVA)
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

Angle formed between the horizontal line at the C7 spinous process and the line connecting C7 to the ipsilateral ear tragus, measured by lateral photogrammetry using standardized adhesive markers and Kinovea software. A lower CVA indicates greater forward head posture (normal > 52°).
Baseline (Week 0), Week 4, Week 8, Week 12

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Rounded Shoulder Posture Angle (RSP)
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

Angle between the line connecting the C7 spinous process to the right acromion and the horizontal, measured by lateral photogrammetry (Kinovea). Values > 52° indicate rounded shoulder posture.
Baseline (Week 0), Week 4, Week 8, Week 12
Thoracic Kyphosis Angle - Bubble Inclinometer
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

Single-inclinometer sequential method: the instrument (Baseline, Fabrication Enterprises Inc., White Plains, NY) is zeroed at T1 and the angle is read at T12. Three measurements per time point; mean used for analysis.
Baseline (Week 0), Week 4, Week 8, Week 12
Thoracic Kyphosis Angle - Smartphone Inclinometer
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

Same T1-T12 sequential method using the Clinometer app (Plaincode) on iPhone 17. The upper corner of the narrow side of the phone is placed at T1 (zeroed to 0°), then moved to T12 (angle read). Three measurements per time point; mean used for analysis.
Baseline (Week 0), Week 4, Week 8, Week 12
Pain Intensity - Visual Analogue Scale (VAS)
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

100-mm horizontal VAS (0 = no pain; 100 = worst imaginable pain) for neck and interscapular pain during the past week. Minimum clinically important difference (MCID): 15 mm.
Baseline (Week 0), Week 4, Week 8, Week 12
Cervical Disability - Neck Disability Index (NDI)
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

10-item self-reported questionnaire assessing the impact of neck pain on daily activities; total score 0-50. Spanish validated version used. MCID: 5 points (10%). Interpretation: 0-8% no disability; 10-28% mild; 30-48% moderate; 50-64% severe; ≥ 64% complete disability.
Baseline (Week 0), Week 4, Week 8, Week 12
Shoulder Pain and Disability - SPADI
Time Frame: Baseline (Week 0), Week 4, Week 8, Week 12

13-item self-reported questionnaire with two subscales (Pain: 5 items; Disability: 8 items), each item scored 0-10. Total score 0-100 (higher = worse). MCID: 13-18 points. Spanish validated version used.
Baseline (Week 0), Week 4, Week 8, Week 12
Exercise Adherence
Time Frame: Weeks 1-12 (cumulative at each assessment point)

Percentage of prescribed sessions completed out of 36 planned sessions (3/week × 12 weeks), recorded in standardized session diaries. Adequate adherence defined as ≥ 70%
Weeks 1-12 (cumulative at each assessment point)
Forced Vital Capacity (FVC, % predicted)
Time Frame: Baseline (Week 0), Week 12

Spirometric measurement (forced vital capacity as percentage of age-sex-height-weight predicted value). ATS acceptability and reproducibility criteria applied; 3 measurements per session, mean used.
Baseline (Week 0), Week 12
FEV₁/FVC Ratio (% predicted)
Time Frame: Baseline (Week 0), Week 12

Ratio of forced expiratory volume in 1 second to forced vital capacity, expressed as percentage of predicted value.
Baseline (Week 0), Week 12
Maximum Voluntary Ventilation (MVV, % predicted)
Time Frame: Baseline (Week 0), Week 12

Spirometric measure of maximum airflow over 12-15 seconds, expressed as percentage of predicted value.
Baseline (Week 0), Week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cardenal Herrera University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 9, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 9, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 29, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 9, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 9, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CEEI26_865
  • CEEI26_865 (Other Identifier: CardenalHU)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings